Randomized, double-blind, placebo-controlled trial (KEYNOTE-522) Previously untreated stage II or III triple-negative breast cancer Neoadjuvant/adjuvant pembrolizumab (n=784) or pl

26 Nov

Diffuse Large B Cell Lymphoma

New Indication: Polatuzumab in Untreated DLBCL

Double-blind Phase III trial Untreated intermediate-risk or high-risk DLBCL Polatuzumab-R-CHP vs R-CHOP

26 Nov

Non-Small Cell Lung Cancer

New Drug: Selpercatinib in RET-Fusion Positive NSCLC

Open-label phase 1–2 trial Previously platinum-based chemotherapy Advanced or metastatic RET fusion positive NSCLC pts who had been treated with platinum (phase I: 49 pts) and wh

26 Nov

Non-Small Cell Lung Cancer

New Indication: Adjuvant Pembrolizumab in NSCLC

Randomised, triple-blind, phase 3 trial Stage IB (tumours of ≥4 cm in diameter), II, or IIIA NSCLC Pembrolizumab 200 mg (590) or placebo (587) / 3 weeks-18 cycles

26 Nov

Other diagnosis

New Indication: Avelumab and Axitinib in Thymic Carcinoma

Single-arm, multicentre, phase 2 trial Had received at least one line of platinum-based chemotherapy Advanced stage thymoma or thymic carcinoma Avelumab 10 mg/kg/14 day and axitini

14 Jun

Bladder Cancer

New Indication: Durvalumab with CISplatin and Gemcitabine in Biliary Tract Cancers

Double-blind, placebo-controlled, phase 3 study Untreated unresectable or metastatic biliary tract cancer Gemcitabine – cisplatin plus Durvalumab (341) or placebo (344)

14 Jun

Skin Cancer (Other than Melanoma)

New Indication: Neoadjuvant Cemiplimab for Cutaneous Squamous Cell Cancer

Phase 2, confirmatory, multicenter, nonrandomized study Resectable stage II, III, or IV (M0) cutaneous squamous-cell carcinoma Cemiplimab 350 mg/21 day (four doses) before surgery

14 Jun

Diffuse Large B Cell Lymphoma

New Protocol: Rituximab, Lenalidomide, and Ibrutinib in DLBCL

Open-label, single-center, phase II study Previously untreated non-GCB DLBCL 60 patients Rituximab 375 mg/m2 (D1), lenalidomide 25 mg D(1-10), and ibrutinib 560 mg continuously (RL

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries